Lyell Immunopharma, Inc. — Director's Dealing 2022

Sep 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2022-09-08

Reporting Person: Bishop Hans Edgar (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-08	Common Stock	M	145380	$0.10	Acquired	4685614	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-08	Option (right to buy)	$0.10	M	145380	Disposed	2028-11-05	Common Stock (145380)	Direct

Footnotes

F1: 1/4 of the option shares vested on September 20, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.